UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction

Benzinga01:27 ET

Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today

Kevin Travers16:21 ET

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

Benzinga15:30 ET

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Benzinga13:18 ET

Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock

Kevin Travers11:21 ET

This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

BenzingaNov 18 10:11 ET